At close: December 13 at 4:00:01 PM EST
After hours: December 13 at 4:20:00 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 4 | 9 | 9 |
| Avg. Estimate | 0.79 | 0.61 | 3.1 | 2.91 |
| Low Estimate | 0.57 | 0.29 | 2.85 | 0.98 |
| High Estimate | 0.91 | 0.84 | 3.43 | 3.7 |
| Year Ago EPS | 0.89 | 0.62 | 2.81 | 3.1 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 3 | 8 | 8 |
| Avg. Estimate | 180.22M | 154.26M | 694.24M | 675.37M |
| Low Estimate | 170.57M | 134.3M | 684.28M | 453.1M |
| High Estimate | 186.3M | 170.7M | 700M | 768.16M |
| Year Ago Sales | 181.24M | 167.12M | 674.98M | 694.24M |
| Sales Growth (year/est) | -0.57% | -7.69% | 2.85% | -2.72% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.87 | 0.62 | 0.7 | 0.7 |
| EPS Actual | 0.89 | 0.62 | 0.89 | 0.79 |
| Difference | 0.02 | -0 | 0.19 | 0.09 |
| Surprise % | 2.18% | -0.70% | 27.30% | 12.07% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.79 | 0.61 | 3.1 | 2.91 |
| 7 Days Ago | 0.78 | 0.62 | 3.12 | 2.84 |
| 30 Days Ago | 0.81 | 0.66 | 2.99 | 2.95 |
| 60 Days Ago | 0.82 | 0.66 | 3.02 | 3.02 |
| 90 Days Ago | 0.82 | 0.66 | 3.02 | 3.02 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | -- | 1 |
| Up Last 30 Days | 5 | 1 | 7 | 3 |
| Down Last 7 Days | -- | 3 | -- | -- |
| Down Last 30 Days | 4 | 3 | 2 | 6 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| PCRX | -11.69% | -1.13% | 10.32% | -6.00% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/4/2024 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 11/12/2024 |
| Reiterates | Needham: Buy to Buy | 11/8/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 11/7/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 10/4/2024 |
| Maintains | Jefferies: Buy to Buy | 9/24/2024 |
Related Tickers
IRWD Ironwood Pharmaceuticals, Inc.
3.5300
-0.84%
ANIK Anika Therapeutics, Inc.
17.16
-0.98%
DVAX Dynavax Technologies Corporation
12.96
-0.23%
AMRX Amneal Pharmaceuticals, Inc.
7.83
-1.14%
LFCR Lifecore Biomedical, Inc.
7.61
+0.40%
SUPN Supernus Pharmaceuticals, Inc.
36.17
+0.03%
COLL Collegium Pharmaceutical, Inc.
30.09
0.00%
ITCI Intra-Cellular Therapies, Inc.
83.03
-0.44%
ETON Eton Pharmaceuticals, Inc.
12.35
+1.56%
EOLS Evolus, Inc.
11.51
-0.60%